Beijing-based Alphax Bio, a developer of immune-testing technologies, has reportedly raised “tens of millions” of renminbi in a recent financing round, led solely by Cui Capital. The funds will be directed towards the clinical transformation of spatial proteomics tumor immune microenvironment assessment, the development of functional proteomics solutions, and the promotion of clinical scenario applications.
About Alphax Bio and Its AlphaTSA Kit
Founded in 2018, Alphax Bio is known for its AlphaTSA Multiplex IHC Kit. The AlphaTSA 7-color kit became the first IVD-certified product in China in July of the previous year. This achievement highlights the company’s commitment to advancing immune-testing technologies.
Spatial Proteomics and Its Applications
Spatial proteomics involves the in situ expression profile of proteins based on different types of cells and functional regions of tissue. By combining spatial information, cell type information, and proteomic data, this technology provides insights into the spatial microenvironment of tissues. It enables more accurate reflection of specific cell functions and states, facilitating the discovery of more precise biomarkers and new functional mechanisms.-Fineline Info & Tech
